A spokesperson for Eli Lilly told Scientific American that the trial used 7 mg and 14 mg doses of oral semaglutide because they were the only approved doses for type 2 diabetes at the time this trial was designed and executed, adding that the results should be interpreted within the context of the doses studied. If approved by the FDA, orforglipron will be available in six doses1 mg, 3 mg, 6 mg, 12 mg, 24 mg and 36 mgthe spokesperson said
These pathways include branded FDA-approved formulations, telehealth-facilitated programs, and compounded semaglutide provided under physician supervision
For companies engaged in compounding of GLP-1 drug products, the warnings signal a need to reassess labeling, advertising, and promotional strategies
Weekly injections are longer-acting, while daily oral drops offer a needle-free alternative
Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]
So, thats a whole other conversation, but it is very similar where we want to look at intelligent use
